ALNYLAM PHARMACEUTICALS, INC. — Director's Dealing 2018

Aug 23, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK: 0001178670
Period of Report: 2018-08-21

Reporting Person: MARAGANORE JOHN (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-21	Performance Stock Option 2015 (right to buy)	$88.95	A	16250	Acquired	2025-12-18	Common Stock (16250)	Direct

Footnotes

F1: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares.